Neuroendocrine Tumors Disease – Global Clinical Trials Review, H1 2020

Pages: 450 Published: May 30, 2020 Report Code: GDHC6216CTIDB

GlobalData's clinical trial report, “Neuroendocrine Tumors Global Clinical Trials Review, H1, 2020" provides an overview of Neuroendocrine Tumors Clinical trials scenario. This report provides top line data relating to the clinical trials on Neuroendocrine Tumors. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

  • Novartis AG

    Ipsen SA

    Pfizer Inc

    F. Hoffmann-La Roche Ltd

    Bristol-Myers Squibb Co

    Lexicon Pharmaceuticals Inc

    Merck & Co Inc

    Eli Lilly and Co

    Amgen Inc

    Progenics Pharmaceuticals Inc

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Neuroendocrine Tumors to Oncology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Neuroendocrine Tumors to Oncology Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Neuroendocrine Tumors Therapeutics Clinical Trials 30

Prominent Drugs 32

Clinical Trial Profile Snapshots 33

Appendix 452

Abbreviations 452

Definitions 452

Research Methodology 453

Secondary Research 453

About GlobalData 454

Contact Us 454

Disclaimer 454

Source 455

List of Tables

List of Tables

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Region, 2020* 7

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 9

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 10

Neuroendocrine Tumors Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020* 11

Neuroendocrine Tumors Therapeutics Clinical Trials, Europe, Top Five Countries, 2020* 12

Neuroendocrine Tumors Therapeutics Clinical Trials, North America, Top Countries, 2020* 13

Neuroendocrine Tumors Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020* 14

Neuroendocrine Tumors Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020* 15

Proportion of Neuroendocrine Tumors to Oncology Clinical Trials, G7 Countries (%), 2020* 16

Neuroendocrine Tumors Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 17

Neuroendocrine Tumors Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 18

Proportion of Neuroendocrine Tumors to Oncology Clinical Trials, E7 Countries (%), 2020* 19

Neuroendocrine Tumors Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 20

Neuroendocrine Tumors Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 21

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Phase, 2020* 22

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials In Progress by Phase 2020* 23

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Trial Status, 2020* 24

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, by End Point Status, 2020* 25

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 26

Neuroendocrine Tumors Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020* 27

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 29

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 31

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 32

List of Figures

List of Figures

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Region (%), 2020* 7

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 8

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 10

Neuroendocrine Tumors Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020* 11

Neuroendocrine Tumors Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020* 12

Neuroendocrine Tumors Therapeutics Clinical Trials, North America, Top Countries (%), 2020* 13

Neuroendocrine Tumors Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020* 14

Neuroendocrine Tumors Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020* 15

Proportion of Neuroendocrine Tumors to Oncology Clinical Trials, G7 Countries (%), 2020* 16

Neuroendocrine Tumors Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 17

Neuroendocrine Tumors Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 18

Proportion of Neuroendocrine Tumors to Oncology Clinical Trials, E7 Countries (%), 2020* 19

Neuroendocrine Tumors Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 20

Neuroendocrine Tumors Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 21

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Phase (%), 2020* 22

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials In Progress by Phase, 2020* 23

Neuroendocrine Tumors Therapeutics, Global, Clinical Trials by Trial Status, 2020* 24

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, by End Point Status, 2020* 25

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 26

Neuroendocrine Tumors Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020* 27

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 28

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 30

Neuroendocrine Tumors Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 32

GlobalData Methodology 453

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.